• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT NPORT-P filed by Daxor Corporation

    9/2/25 6:09:18 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care
    Get the next $DXR alert in real time by email
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    FORM NPORT-P
    Monthly Portfolio Investments Report

    NPORT-P: Filer Information

    Filer CIK
    0000027367 
    Filer CCC
    ********  
    Filer Investment Company Type
     
    Is this a LIVE or TEST Filing? live is not checked LIVE test is not checked TEST
    Would you like a Return Copy? return copy flag is not checked
    Is this an electronic copy of an official filing submitted in paper format? Confirm flag is not checked

    Submission Contact Information

    Name
     
    Phone
     
    E-Mail Address
     

    Notification Information

    Notify via Filing Website only?Override internet flag is not checked
    Series ID
     

    NPORT-P: Part A: General Information

    Item A.1. Information about the Registrant.

    a. Name of Registrant
    DAXOR CORP 
    b. Investment Company Act file number for Registrant: (e.g., 811-______)
    811-22684 
    c. CIK number of Registrant
    0000027367 
    d. LEI of Registrant
    984500B839ED8XIK6792 

    e. Address and telephone number of Registrant.
    Street Address 1
    109 Meco Lane 
    Street Address 2
     
    City
    Oak Ridge 
    State, if applicable
    NEW YORK  
    Foreign country, if applicable
    UNITED STATES OF AMERICA  
    Zip / Postal Code
    37830 
    Telephone number
    516-317-2670 

    Item A.2. Information about the Series.

    a. Name of Series.
    None 
    b. EDGAR series identifier (if any).
     
    c. LEI of Series.
    00000000000000000000 

    Item A.3. Reporting period.

    a. Date of fiscal year-end.
    2025-12-31 
    b. Date as of which information is reported.
    2025-06-30 

    Item A.4. Final filing

    Does the Fund anticipate that this will be its final filing on Form N PORT?Yes is not checked Yes No is checked No

    NPORT-P: Part B: Information About the Fund

    Report the following information for the Fund and its consolidated subsidiaries.

    Item B.1. Assets and liabilities. Report amounts in U.S. dollars.

    a. Total assets, including assets attributable to miscellaneous securities reported in Part D.
    35900243.00 
    b. Total liabilities.
    272427.00 
    c. Net assets.
    35627816.00 

    Item B.2. Certain assets and liabilities. Report amounts in U.S. dollars.

    a. Assets attributable to miscellaneous securities reported in Part D.
    35500000.00 
    b. Assets invested in a Controlled Foreign Corporation for the purpose of investing in certain types of instruments such as, but not limited to, commodities.
    0 

    c. Borrowings attributable to amounts payable for notes payable, bonds, and similar debt, as reported pursuant to rule 6-04(13)(a) of Regulation S-X [17 CFR 210.6-04(13)(a)].

    Amounts payable within one year.
    Banks or other financial institutions for borrowings.
    272427.00 
    Controlled companies.
    0 
    Other affiliates.
    0 
    Others.
    0 
    Amounts payable after one year.
    Banks or other financial institutions for borrowings.
    0 
    Controlled companies.
    0 
    Other affiliates.
    0 
    Others.
    0 

    d. Payables for investments purchased either (i) on a delayed delivery, when-issued, or other firm commitment basis, or (ii) on a standby commitment basis.

    (i) On a delayed delivery, when-issued, or other firm commitment basis:
    0 
    (ii) On a standby commitment basis:
    0 
    e. Liquidation preference of outstanding preferred stock issued by the Fund.
    0 
    f. Cash and cash equivalents not reported in Parts C and D.
    0 

    Item B.3. Portfolio level risk metrics.

    If the average value of the Fund's debt securities positions for the previous three months, in the aggregate, exceeds 25% or more of the Fund's net asset value, provide:

    c. Credit Spread Risk (SDV01, CR01 or CS01). Provide the change in value of the portfolio resulting from a 1 basis point change in credit spreads where the shift is applied to the option adjusted spread, aggregated by investment grade and non-investment grade exposures, for each of the following maturities: 3 month, 1 year, 5 years, 10 years, and 30 years.

    Investment grade.
    Maturity period.
    3 month.
     
    1 year.
     
    5 years.
     
    10 years.
     
    30 years.
     
    Non-Investment grade.
    Maturity period.
    3 month.
     
    1 year.
     
    5 years.
     
    10 years.
     
    30 years.
     

    For purposes of Item B.3., calculate value as the sum of the absolute values of:
    (i) the value of each debt security,
    (ii) the notional value of each swap, including, but not limited to, total return swaps, interest rate swaps, and credit default swaps, for which the underlying reference asset or assets are debt securities or an interest rate;
    (iii) the notional value of each futures contract for which the underlying reference asset or assets are debt securities or an interest rate; and
    (iv) the delta-adjusted notional value of any option for which the underlying reference asset is an asset described in clause (i),(ii), or (iii).

    Report zero for maturities to which the Fund has no exposure. For exposures that fall between any of the listed maturities in (a) and (b), use linear interpolation to approximate exposure to each maturity listed above. For exposures outside of the range of maturities listed above, include those exposures in the nearest maturity.


    Item B.4. Securities lending.

    a. For each borrower in any securities lending transaction, provide the following information:

    b. Did any securities lending counterparty provide any non-cash collateral? Radio button not checked Yes Radio button checked No

    Item B.5. Return information.

    a. Monthly total returns of the Fund for each of the preceding three months. If the Fund is a Multiple Class Fund, report returns for each class. Such returns shall be calculated in accordance with the methodologies outlined in Item 26(b) (1) of Form N-1A, Instruction 13 to sub-Item 1 of Item 4 of Form N-2, or Item 26(b) (i) of Form N-3, as applicable.

    Monthly Total Return Record: 1
    Monthly total returns of the Fund for each of the preceding three months – Month 1.
    0 
    Monthly total returns of the Fund for each of the preceding three months – Month 2.
    0 
    Monthly total returns of the Fund for each of the preceding three months – Month 3.
    0 
    b. Class identification number(s) (if any) of the Class(es) for which returns are reported.
     

    c. For each of the preceding three months, monthly net realized gain (loss) and net change in unrealized appreciation (or depreciation) attributable to derivatives for each of the following categories: commodity contracts, credit contracts, equity contracts, foreign exchange contracts, interest rate contracts, and other contracts. Within each such asset category, further report the same information for each of the following types of derivatives instrument: forward, future, option, swaption, swap, warrant, and other. Report in U.S. dollars. Losses and depreciation shall be reported as negative numbers.

    Asset category.
    Equity Contracts
    Monthly net realized gain(loss) – Month 1
    0 
    Monthly net change in unrealized appreciation (or depreciation) – Month 1
    0.00 
    Monthly net realized gain(loss) – Month 2
    0 
    Monthly net change in unrealized appreciation (or depreciation) – Month 2
    0.00 
    Monthly net realized gain(loss) – Month 3
    0 
    Monthly net change in unrealized appreciation (or depreciation) – Month 3
    0.00 
    Instrument type.
    Option
    Monthly net realized gain(loss) – Month 1
    0 
    Monthly net change in unrealized appreciation (or depreciation) – Month 1
    0.00 
    Monthly net realized gain(loss) – Month 2
    0 
    Monthly net change in unrealized appreciation (or depreciation) – Month 2
    0.00 
    Monthly net realized gain(loss) – Month 3
    0 
    Monthly net change in unrealized appreciation (or depreciation) – Month 3
    0.00 

    d. For each of the preceding three months, monthly net realized gain (loss) and net change in unrealized appreciation (or depreciation) attributable to investment other than derivatives. Report in U.S. dollars. Losses and depreciation shall be reported as negative numbers.
    Month 1


    Monthly net realized gain(loss) – Month 1
    0 
    Monthly net change in unrealized appreciation (or depreciation) – Month 1
    2132.00 
    Month 2
    Monthly net realized gain(loss) – Month 2
    0 
    Monthly net change in unrealized appreciation (or depreciation) – Month 2
    3812.00 
    Month 3
    Monthly net realized gain(loss) – Month 3
    33101.00 
    Monthly net change in unrealized appreciation (or depreciation) – Month 3
    -40153.00 

    Item B.6. Flow information.

    Provide the aggregate dollar amounts for sales and redemptions/repurchases of Fund shares during each of the preceding three months. If shares of the Fund are held in omnibus accounts, for purposes of calculating the Fund's sales, redemptions, and repurchases, use net sales or redemptions/repurchases from such omnibus accounts. The amounts to be reported under this Item should be after any front-end sales load has been deducted and before any deferred or contingent deferred sales load or charge has been deducted. Shares sold shall include shares sold by the Fund to a registered unit investment trust. For mergers and other acquisitions, include in the value of shares sold any transaction in which the Fund acquired the assets of another investment company or of a personal holding company in exchange for its own shares. For liquidations, include in the value of shares redeemed any transaction in which the Fund liquidated all or part of its assets. Exchanges are defined as the redemption or repurchase of shares of one Fund or series and the investment of all or part of the proceeds in shares of another Fund or series in the same family of investment companies.
    Month 1
    a. Total net asset value of shares sold (including exchanges but excluding reinvestment of dividends and distributions).
    0 
    b. Total net asset value of shares sold in connection with reinvestments of dividends and distributions.
    0 
    c. Total net asset value of shares redeemed or repurchased, including exchanges.
    0 
    Month 2
    a. Total net asset value of shares sold (including exchanges but excluding reinvestment of dividends and distributions).
    0 
    b. Total net asset value of shares sold in connection with reinvestments of dividends and distributions.
    0 
    c. Total net asset value of shares redeemed or repurchased, including exchanges.
    0 
    Month 3
    a. Total net asset value of shares sold (including exchanges but excluding reinvestment of dividends and distributions).
    0 
    b. Total net asset value of shares sold in connection with reinvestments of dividends and distributions.
    0 
    c. Total net asset value of shares redeemed or repurchased, including exchanges.
    0 

    Item B.7. Highly Liquid Investment Minimum information.

    a. If applicable, provide the Fund's current Highly Liquid Investment Minimum.
     
    b. If applicable, provide the number of days that the Fund's holdings in Highly Liquid Investments fell below the Fund's Highly Liquid Investment Minimum during the reporting period.
     
    c. Did the Fund's Highly Liquid Investment Minimum change during the reporting period? Yes is not checked Yes No is not checked No N/A is not checked N/A

    Item B.8. Derivatives Transactions.

    For portfolio investments of open-end management investment companies, provide the percentage of the Fund's Highly Liquid Investments that it has pledged as margin or collateral in connection with derivatives transactions that are classified among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]:

    (1) Moderately Liquid Investments
    (2) Less Liquid Investments
    (3) Illiquid Investments

    For purposes of Item B.8, when computing the required percentage, the denominator should only include assets (and exclude liabilities) that are categorized by the Fund as Highly Liquid Investments.

    Classification
     

    Item B.9. Derivatives Exposure for limited derivatives users.

    If the Fund is excepted from the rule 18f-4 [17 CFR 270.18f-4] program requirement and limit on fund leverage risk under rule 18f-4(c)(4) [17 CFR 270.18f-4(c)(4)], provide the following information:

    a. Derivatives exposure (as defined in rule 18f-4(a) [17 CFR 270.18f-4(a)]), reported as a percentage of the Fund’s net asset value.
     
    b. Exposure from currency derivatives that hedge currency risks, as provided in rule 18f-4(c)(4)(i)(B) [17 CFR 270.18f-4(c)(4)(i)(B)], reported as a percentage of the Fund's net asset value.
     
    c. Exposure from interest rate derivatives that hedge interest rate risks, as provided in rule 18f-4(c)(4)(i)(B) [17 CFR 270.18f-4(c)(4)(i)(B)], reported as a percentage of the Fund's net asset value.
     
    d. The number of business days, if any, in excess of the five-business-day period described in rule 18f-4(c)(4)(ii) [17 CFR 270.18f-4(c)(4)(ii)], that the Fund’s derivatives exposure exceeded 10 percent of its net assets during the reporting period.
     

    Item B.10. VaR information.

    For Funds subject to the limit on fund leverage risk described in rule 18f-4(c)(2) [17 CFR 270.18f-4(c)(2)], provide the following information, as determined in accordance with the requirement under rule 18f-4(c)(2)(ii) to determine the fund’s compliance with the applicable VaR test at least once each business day:

    a. Median daily VaR during the reporting period, reported as a percentage of the Fund's net asset value.
     
    b. For Funds that were subject to the Relative VaR Test during the reporting period, provide:
    i. As applicable, the name of the Fund’s Designated Index, or a statement that the Fund's Designated Reference Portfolio is the Fund’s Securities Portfolio.
     
    ii. As applicable, the index identifier for the Fund’s Designated Index.
     
    iii. Median VaR Ratio during the reporting period, reported as a percentage of the VaRof the Fund's Designated Reference Portfolio.
     
    c. Backtesting Results. Number of exceptions that the Fund identified as a result of its backtesting of its VaR calculation model (as described in rule 18f-4(c)(1)(iv) [17 CFR 270.18f-4(c)(1)(iv)] during the reporting period.
     

    NPORT-P: Part C: Schedule of Portfolio Investments

    For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

    Item C.1. Identification of investment.

    a. Name of issuer (if any).
    Enbridge Inc. 
    b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
    5493003FRODSVHJWFS32 
    c. Title of the issue or description of the investment.
    Common Stock 
    d. CUSIP (if any).
    29250N105 

    At least one of the following other identifiers:

    Identifier.
    ISIN
    ISIN
    CA29250N1050 
    Identifier.
    Ticker (if ISIN is not available)
    Ticker (if ISIN is not available).
    ENB 
    Identifier.
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    None 
    Description of other unique identifier.
    None 

    Item C.2. Amount of each investment.

    Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

    Balance
    2952 
    Units
    Number of shares  
    Description of other units.
     
    Currency. Indicate the currency in which the investment is denominated.
    United States Dollar  
    Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
    133785.00 
    Exchange rate.
     
    Percentage value compared to net assets of the Fund.
    0.38 

    Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

    Payoff profile. Long is checked Long Short is not checked Short N/A is not checked N/A

    Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

    Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If “other,” provide a brief description.
    Equity-common  
    Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If “other”, provide a brief description.
    Corporate  

    Item C.5. Country of investment or issuer.

    Report the ISO country code that corresponds to the country where the issuer is organized.
    UNITED STATES OF AMERICA  
    If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.
     

    Item C.6. Is the investment a Restricted Security?

    Is the investment a Restricted Security? Yes is not checked Yes No is checked No

    Item C.7.

    a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

    i. Highly Liquid Investments
    ii. Moderately Liquid Investments
    iii. Less Liquid Investments
    iv. Illiquid Investments
    Category.
    N/A  

    b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

    Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

    Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report “N/A” if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

    Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 is checked 1 2 is not checked 2 3 is not checked 3 N/A is not checked N/A

    Item C.9. For debt securities

    For debt securities, also provide:

    a. Maturity date.
     

    b. Coupon.

    i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
     
    ii. Annualized rate.
     
    c. Currently in default? [Y/N]Yes is not checked Yes No is not checked No
    d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes is not checked Yes No is not checked No
    e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes is not checked Yes No is not checked No

    f. For convertible securities, also provide:

    i. Mandatory convertible? [Y/N] Yes is not checked Yes No is not checked No
    ii. Contingent convertible? [Y/N] Yes is not checked Yes No is not checked No

    iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
    If other identifier provided, indicate the type of identifier used.

    v. Delta (if applicable).
     

    Item C.10. For repurchase and reverse repurchase agreements, also provide:

    a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase is not checked Repurchase Reverse repurchase is not checked Reverse repurchase

    b. Counterparty.

    i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes is not checked Yes No is not checked No

    ii. If N, provide the name and LEI (if any) of counterparty.

    c. Tri-party? Yes is not checked Yes No is not checked No
    d. Repurchase rate.
     
    e. Maturity date.
     

    f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

    Item C.11. For derivatives, also provide:

    Item C.12. Securities lending.

    a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes is not checked Yes No is checked No
    b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes is not checked Yes No is checked No
    c. Is any portion of this investment on loan by the Fund? Yes is not checked Yes No is checked No

    NPORT-P: Part C: Schedule of Portfolio Investments

    For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

    Item C.1. Identification of investment.

    a. Name of issuer (if any).
    Eversource Energy 
    b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
    SJ7XXD41SQU3ZNWUJ746 
    c. Title of the issue or description of the investment.
    Common Stock 
    d. CUSIP (if any).
    664397106 

    At least one of the following other identifiers:

    Identifier.
    ISIN
    ISIN
    US30040W1080 
    Identifier.
    Ticker (if ISIN is not available)
    Ticker (if ISIN is not available).
    ES 
    Identifier.
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    None 
    Description of other unique identifier.
    None 

    Item C.2. Amount of each investment.

    Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

    Balance
    1300 
    Units
    Number of shares  
    Description of other units.
     
    Currency. Indicate the currency in which the investment is denominated.
    United States Dollar  
    Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
    82706.00 
    Exchange rate.
     
    Percentage value compared to net assets of the Fund.
    0.23 

    Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

    Payoff profile. Long is checked Long Short is not checked Short N/A is not checked N/A

    Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

    Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If “other,” provide a brief description.
    Equity-common  
    Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If “other”, provide a brief description.
    Corporate  

    Item C.5. Country of investment or issuer.

    Report the ISO country code that corresponds to the country where the issuer is organized.
    UNITED STATES OF AMERICA  
    If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.
     

    Item C.6. Is the investment a Restricted Security?

    Is the investment a Restricted Security? Yes is not checked Yes No is checked No

    Item C.7.

    a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

    i. Highly Liquid Investments
    ii. Moderately Liquid Investments
    iii. Less Liquid Investments
    iv. Illiquid Investments
    Category.
    N/A  

    b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

    Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

    Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report “N/A” if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

    Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 is checked 1 2 is not checked 2 3 is not checked 3 N/A is not checked N/A

    Item C.9. For debt securities

    For debt securities, also provide:

    a. Maturity date.
     

    b. Coupon.

    i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
     
    ii. Annualized rate.
     
    c. Currently in default? [Y/N]Yes is not checked Yes No is not checked No
    d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes is not checked Yes No is not checked No
    e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes is not checked Yes No is not checked No

    f. For convertible securities, also provide:

    i. Mandatory convertible? [Y/N] Yes is not checked Yes No is not checked No
    ii. Contingent convertible? [Y/N] Yes is not checked Yes No is not checked No

    iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
    If other identifier provided, indicate the type of identifier used.

    v. Delta (if applicable).
     

    Item C.10. For repurchase and reverse repurchase agreements, also provide:

    a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase is not checked Repurchase Reverse repurchase is not checked Reverse repurchase

    b. Counterparty.

    i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes is not checked Yes No is not checked No

    ii. If N, provide the name and LEI (if any) of counterparty.

    c. Tri-party? Yes is not checked Yes No is not checked No
    d. Repurchase rate.
     
    e. Maturity date.
     

    f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

    Item C.11. For derivatives, also provide:

    Item C.12. Securities lending.

    a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes is not checked Yes No is checked No
    b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes is not checked Yes No is checked No
    c. Is any portion of this investment on loan by the Fund? Yes is not checked Yes No is checked No

    NPORT-P: Part C: Schedule of Portfolio Investments

    For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

    Item C.1. Identification of investment.

    a. Name of issuer (if any).
    Evergy Inc 
    b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
    549300PGTHDQY6PSUI61 
    c. Title of the issue or description of the investment.
    Common Stock 
    d. CUSIP (if any).
    30034W106 

    At least one of the following other identifiers:

    Identifier.
    ISIN
    ISIN
    US30034W1062 
    Identifier.
    Ticker (if ISIN is not available)
    Ticker (if ISIN is not available).
    EVRG 
    Identifier.
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    None 
    Description of other unique identifier.
    None 

    Item C.2. Amount of each investment.

    Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

    Balance
    697 
    Units
    Number of shares  
    Description of other units.
     
    Currency. Indicate the currency in which the investment is denominated.
    United States Dollar  
    Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
    48044.00 
    Exchange rate.
     
    Percentage value compared to net assets of the Fund.
    0.13 

    Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

    Payoff profile. Long is checked Long Short is not checked Short N/A is not checked N/A

    Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

    Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If “other,” provide a brief description.
    Equity-common  
    Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If “other”, provide a brief description.
    Corporate  

    Item C.5. Country of investment or issuer.

    Report the ISO country code that corresponds to the country where the issuer is organized.
    UNITED STATES OF AMERICA  
    If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.
     

    Item C.6. Is the investment a Restricted Security?

    Is the investment a Restricted Security? Yes is not checked Yes No is checked No

    Item C.7.

    a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

    i. Highly Liquid Investments
    ii. Moderately Liquid Investments
    iii. Less Liquid Investments
    iv. Illiquid Investments
    Category.
    N/A  

    b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

    Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

    Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report “N/A” if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

    Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 is checked 1 2 is not checked 2 3 is not checked 3 N/A is not checked N/A

    Item C.9. For debt securities

    For debt securities, also provide:

    a. Maturity date.
     

    b. Coupon.

    i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
     
    ii. Annualized rate.
     
    c. Currently in default? [Y/N]Yes is not checked Yes No is not checked No
    d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes is not checked Yes No is not checked No
    e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes is not checked Yes No is not checked No

    f. For convertible securities, also provide:

    i. Mandatory convertible? [Y/N] Yes is not checked Yes No is not checked No
    ii. Contingent convertible? [Y/N] Yes is not checked Yes No is not checked No

    iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
    If other identifier provided, indicate the type of identifier used.

    v. Delta (if applicable).
     

    Item C.10. For repurchase and reverse repurchase agreements, also provide:

    a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase is not checked Repurchase Reverse repurchase is not checked Reverse repurchase

    b. Counterparty.

    i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes is not checked Yes No is not checked No

    ii. If N, provide the name and LEI (if any) of counterparty.

    c. Tri-party? Yes is not checked Yes No is not checked No
    d. Repurchase rate.
     
    e. Maturity date.
     

    f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

    Item C.11. For derivatives, also provide:

    Item C.12. Securities lending.

    a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes is not checked Yes No is checked No
    b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes is not checked Yes No is checked No
    c. Is any portion of this investment on loan by the Fund? Yes is not checked Yes No is checked No

    NPORT-P: Part C: Schedule of Portfolio Investments

    For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

    Item C.1. Identification of investment.

    a. Name of issuer (if any).
    Centrus Energy Corp. 
    b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
    549300G6VDK9G8276661 
    c. Title of the issue or description of the investment.
    Common Stock 
    d. CUSIP (if any).
    15643U104 

    At least one of the following other identifiers:

    Identifier.
    ISIN
    ISIN
    US15643U1043 
    Identifier.
    Ticker (if ISIN is not available)
    Ticker (if ISIN is not available).
    LEU 
    Identifier.
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    None 
    Description of other unique identifier.
    None 

    Item C.2. Amount of each investment.

    Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

    Balance
    1 
    Units
    Number of shares  
    Description of other units.
     
    Currency. Indicate the currency in which the investment is denominated.
    United States Dollar  
    Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
    183.00 
    Exchange rate.
     
    Percentage value compared to net assets of the Fund.
    0.00 

    Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

    Payoff profile. Long is checked Long Short is not checked Short N/A is not checked N/A

    Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

    Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If “other,” provide a brief description.
    Equity-common  
    Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If “other”, provide a brief description.
    Corporate  

    Item C.5. Country of investment or issuer.

    Report the ISO country code that corresponds to the country where the issuer is organized.
    UNITED STATES OF AMERICA  
    If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.
     

    Item C.6. Is the investment a Restricted Security?

    Is the investment a Restricted Security? Yes is not checked Yes No is checked No

    Item C.7.

    a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

    i. Highly Liquid Investments
    ii. Moderately Liquid Investments
    iii. Less Liquid Investments
    iv. Illiquid Investments
    Category.
    N/A  

    b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

    Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

    Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report “N/A” if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

    Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 is checked 1 2 is not checked 2 3 is not checked 3 N/A is not checked N/A

    Item C.9. For debt securities

    For debt securities, also provide:

    a. Maturity date.
     

    b. Coupon.

    i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
     
    ii. Annualized rate.
     
    c. Currently in default? [Y/N]Yes is not checked Yes No is not checked No
    d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes is not checked Yes No is not checked No
    e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes is not checked Yes No is not checked No

    f. For convertible securities, also provide:

    i. Mandatory convertible? [Y/N] Yes is not checked Yes No is not checked No
    ii. Contingent convertible? [Y/N] Yes is not checked Yes No is not checked No

    iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
    If other identifier provided, indicate the type of identifier used.

    v. Delta (if applicable).
     

    Item C.10. For repurchase and reverse repurchase agreements, also provide:

    a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase is not checked Repurchase Reverse repurchase is not checked Reverse repurchase

    b. Counterparty.

    i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes is not checked Yes No is not checked No

    ii. If N, provide the name and LEI (if any) of counterparty.

    c. Tri-party? Yes is not checked Yes No is not checked No
    d. Repurchase rate.
     
    e. Maturity date.
     

    f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

    Item C.11. For derivatives, also provide:

    Item C.12. Securities lending.

    a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes is not checked Yes No is checked No
    b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes is not checked Yes No is checked No
    c. Is any portion of this investment on loan by the Fund? Yes is not checked Yes No is checked No

    NPORT-P: Part C: Schedule of Portfolio Investments

    For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

    Item C.1. Identification of investment.

    a. Name of issuer (if any).
    Wabtec, Inc 
    b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
    N/A 
    c. Title of the issue or description of the investment.
    Common Stock 
    d. CUSIP (if any).
    929740108 

    At least one of the following other identifiers:

    Identifier.
    ISIN
    ISIN
    US9297401088 
    Identifier.
    Ticker (if ISIN is not available)
    Ticker (if ISIN is not available).
    WAB 
    Identifier.
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    None 
    Description of other unique identifier.
    None 

    Item C.2. Amount of each investment.

    Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

    Balance
    13 
    Units
    Number of shares  
    Description of other units.
     
    Currency. Indicate the currency in which the investment is denominated.
    United States Dollar  
    Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
    2722.00 
    Exchange rate.
     
    Percentage value compared to net assets of the Fund.
    0.01 

    Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

    Payoff profile. Long is checked Long Short is not checked Short N/A is not checked N/A

    Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

    Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If “other,” provide a brief description.
    Equity-common  
    Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If “other”, provide a brief description.
    Corporate  

    Item C.5. Country of investment or issuer.

    Report the ISO country code that corresponds to the country where the issuer is organized.
    UNITED STATES OF AMERICA  
    If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.
     

    Item C.6. Is the investment a Restricted Security?

    Is the investment a Restricted Security? Yes is not checked Yes No is checked No

    Item C.7.

    a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

    i. Highly Liquid Investments
    ii. Moderately Liquid Investments
    iii. Less Liquid Investments
    iv. Illiquid Investments
    Category.
    N/A  

    b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

    Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

    Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report “N/A” if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

    Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 is checked 1 2 is not checked 2 3 is not checked 3 N/A is not checked N/A

    Item C.9. For debt securities

    For debt securities, also provide:

    a. Maturity date.
     

    b. Coupon.

    i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
     
    ii. Annualized rate.
     
    c. Currently in default? [Y/N]Yes is not checked Yes No is not checked No
    d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes is not checked Yes No is not checked No
    e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes is not checked Yes No is not checked No

    f. For convertible securities, also provide:

    i. Mandatory convertible? [Y/N] Yes is not checked Yes No is not checked No
    ii. Contingent convertible? [Y/N] Yes is not checked Yes No is not checked No

    iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
    If other identifier provided, indicate the type of identifier used.

    v. Delta (if applicable).
     

    Item C.10. For repurchase and reverse repurchase agreements, also provide:

    a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase is not checked Repurchase Reverse repurchase is not checked Reverse repurchase

    b. Counterparty.

    i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes is not checked Yes No is not checked No

    ii. If N, provide the name and LEI (if any) of counterparty.

    c. Tri-party? Yes is not checked Yes No is not checked No
    d. Repurchase rate.
     
    e. Maturity date.
     

    f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

    Item C.11. For derivatives, also provide:

    Item C.12. Securities lending.

    a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes is not checked Yes No is checked No
    b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes is not checked Yes No is checked No
    c. Is any portion of this investment on loan by the Fund? Yes is not checked Yes No is checked No

    NPORT-P: Part C: Schedule of Portfolio Investments

    For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.

    Item C.1. Identification of investment.

    a. Name of issuer (if any).
    Bank of America 
    b. LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
    N/A 
    c. Title of the issue or description of the investment.
    Preferred Stock 
    d. CUSIP (if any).
    000000000 

    At least one of the following other identifiers:

    Identifier.
    ISIN
    ISIN
    US0605051046 
    Identifier.
    Ticker (if ISIN is not available)
    Ticker (if ISIN is not available).
    BACPRL 
    Identifier.
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
    None 
    Description of other unique identifier.
    None 

    Item C.2. Amount of each investment.

    Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.

    Balance
    100 
    Units
    Number of shares  
    Description of other units.
     
    Currency. Indicate the currency in which the investment is denominated.
    United States Dollar  
    Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
    121300.00 
    Exchange rate.
     
    Percentage value compared to net assets of the Fund.
    0.34 

    Item C.3. Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item C.11.

    Payoff profile. Long is checked Long Short is not checked Short N/A is not checked N/A

    Item C.4. Asset and issuer type. Select the category that most closely identifies the instrument among each of the following:

    Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If “other,” provide a brief description.
    Equity-preferred  
    Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If “other”, provide a brief description.
    Corporate  

    Item C.5. Country of investment or issuer.

    Report the ISO country code that corresponds to the country where the issuer is organized.
    UNITED STATES OF AMERICA  
    If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.
     

    Item C.6. Is the investment a Restricted Security?

    Is the investment a Restricted Security? Yes is not checked Yes No is checked No

    Item C.7.

    a. Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.

    i. Highly Liquid Investments
    ii. Moderately Liquid Investments
    iii. Less Liquid Investments
    iv. Illiquid Investments
    Category.
    N/A  

    b. If attributing multiple classification categories to the holding, indicate which of the three circumstances listed in the Instructions to Item C.7 is applicable.

    Instructions to Item C.7 Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances: (1) if portions of the position have differing liquidity features that justify treating the portions separately; (2) if a fund has multiple sub-advisers with differing liquidity views; or (3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading). In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.

    Item C.8. Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles (ASC 820, Fair Value Measurement). [1/2/3] Report “N/A” if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).

    Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7(ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient). 1 is checked 1 2 is not checked 2 3 is not checked 3 N/A is not checked N/A

    Item C.9. For debt securities

    For debt securities, also provide:

    a. Maturity date.
     

    b. Coupon.

    i. Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
     
    ii. Annualized rate.
     
    c. Currently in default? [Y/N]Yes is not checked Yes No is not checked No
    d. Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N] Yes is not checked Yes No is not checked No
    e. Is any portion of the interest paid in kind? [Y/N] Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind. Yes is not checked Yes No is not checked No

    f. For convertible securities, also provide:

    i. Mandatory convertible? [Y/N] Yes is not checked Yes No is not checked No
    ii. Contingent convertible? [Y/N] Yes is not checked Yes No is not checked No

    iii. Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
    If other identifier provided, indicate the type of identifier used.

    v. Delta (if applicable).
     

    Item C.10. For repurchase and reverse repurchase agreements, also provide:

    a. Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral. Repurchase is not checked Repurchase Reverse repurchase is not checked Reverse repurchase

    b. Counterparty.

    i. Cleared by central counterparty? [Y/N] If Y, provide the name of the central counterparty. Yes is not checked Yes No is not checked No

    ii. If N, provide the name and LEI (if any) of counterparty.

    c. Tri-party? Yes is not checked Yes No is not checked No
    d. Repurchase rate.
     
    e. Maturity date.
     

    f. Provide the following information concerning the securities subject to the repurchase agreement (i.e., collateral). If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii.

    Item C.11. For derivatives, also provide:

    Item C.12. Securities lending.

    a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes is not checked Yes No is checked No
    b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes is not checked Yes No is checked No
    c. Is any portion of this investment on loan by the Fund? Yes is not checked Yes No is checked No

    NPORT-P: Part E: Explanatory Notes (if any)

    The Fund may provide any information it believes would be helpful in understanding the information reported in response to any Item of this Form. The Fund may also explain any assumptions that it made in responding to any Item of this Form. To the extent responses relate to a particular Item, provide the Item number(s), as applicable.

    NPORT-P: Signatures

    The Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Registrant:
    Daxor Corporation 
    By(Signature):
    /s/ Robert J. Michel 
    Name:
    Robert J. Michel 
    Title:
    Chief Financial Officer, Chief Compliance Officer 
    Date:
    2025-09-02 

    Get the next $DXR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DXR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

    Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will engage institutional investors at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025, at the Hard Rock Hotel in New York City. Mr. Feldschuh will be available for one-on-one meetings with institutional investors and will also meet with senior Maxim analysts throughout the event. The conference features high-profile

    10/21/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor's New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25

    OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'25 Conference being held at the JW Marriott Austin, from Thursday, October 16 - Saturday, October 18 in Austin, TX. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting industry innovators and thought leaders from across the country. "We are thrilled to debut our eagerly awaited next generation BVA diagnostic system at this pivotal gathering," said Michael Feldschuh, Daxor's CEO and President. "This launch

    10/15/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

    Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The company's successful debut of its newly FDA-cleared, next-generation BVA analyzer signals a new era of data-driven fluid management for a multi-billion-dollar market. The initial response from clinicians confirmed robust market demand for the new system, driven b

    9/30/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Jefferies John bought 2,344 units of Daxor Common Stock, increasing direct ownership by 15% to 17,616 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    11/14/25 5:22:37 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Feldschuh Michael Richard bought $16,277 worth of Daxor Common Stock (2,063 units at $7.89), increasing direct ownership by 0.98% to 212,694 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    4/7/25 3:23:29 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Chief Executive Office Feldschuh Michael Richard bought $8,130 worth of Daxor Common Stock (1,000 units at $8.13), increasing direct ownership by 0.48% to 210,631 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    3/27/25 11:46:12 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Jefferies John bought 2,344 units of Daxor Common Stock, increasing direct ownership by 15% to 17,616 units (SEC Form 4)

    4 - DAXOR CORP (0000027367) (Issuer)

    11/14/25 5:22:37 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    New insider Jefferies John claimed ownership of 15,272 units of Daxor Common Stock (SEC Form 3)

    3 - DAXOR CORP (0000027367) (Issuer)

    10/2/25 3:13:38 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Desrosiers Caleb

    4 - DAXOR CORP (0000027367) (Issuer)

    6/26/25 4:24:11 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    SEC Filings

    View All

    Amendment: SEC Form N-2/A filed by Daxor Corporation

    N-2/A - DAXOR CORP (0000027367) (Filer)

    10/20/25 11:40:40 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form N-CSR/A filed by Daxor Corporation

    N-CSR/A - DAXOR CORP (0000027367) (Filer)

    10/15/25 4:25:42 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    SEC Form N-PX filed by Daxor Corporation

    N-PX - DAXOR CORP (0000027367) (Filer)

    9/2/25 5:27:36 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital initiated coverage on Daxor with a new price target

    Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00

    3/25/21 12:00:28 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Leadership Updates

    Live Leadership Updates

    View All

    Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer

    Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe

    6/5/24 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Appoints Linda Cooper, Vice President Project Management

    Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh

    2/17/23 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    $DXR
    Financials

    Live finance-specific insights

    View All

    Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

    Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "Patience, persistence and perspiration make an unbeatable combination for success." – Napoleon Hill. This timeless wisdom resonates deeply with the journey we've undertaken at Daxor Corporation, and it perfectly encapsulates the spirit behind our latest achievements. We are thrilled to share that this persistence has culminated in a truly transformative moment for our company, marking an important

    9/2/25 8:00:00 AM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

    Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D

    3/4/25 4:55:00 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care

    Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

    Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: [email protected]. To participate, register HERE. A webcast replay of the call will be available on the Company's website at Daxor.com. About Daxor Corporation Daxor Corporatio

    3/4/25 3:53:00 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care